Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks

被引:32
作者
Sabourin, M
Nitiss, JL
Nitiss, KC
Tatebayashi, K
Ikeda, H
Osheroff, N
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA
[3] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38101 USA
[4] Univ Tokyo, Inst Med Sci, Div Mol Cell Signaling, Minato Ku, Tokyo 1088639, Japan
[5] Medinet Inc, Inst Med Sci, Kouhoku Ku, Yokohama, Kanagawa 2220033, Japan
关键词
D O I
10.1093/nar/gkg497
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase II is a ubiquitous enzyme that removes knots and tangles from the genetic material by generating transient double-strand DNA breaks. While the enzyme cannot perform its essential cellular functions without cleaving DNA, this scission activity is inherently dangerous to chromosomal integrity. In fact, etoposide and other clinically important anticancer drugs kill cells by increasing levels of topoisomerase II-mediated DNA breaks. Cells rely heavily on recombination to repair double-strand DNA breaks, but the specific pathways used to repair topoisomerase II-generated DNA damage have not been defined. Therefore, Saccharomyces cerevisiae was used as a model system to delineate the recombination pathways that repair DNA breaks generated by topoisomerase II. Yeast cells that expressed wild-type or a drug-hypersensitive mutant topoisomerase II or overexpressed the wild-type enzyme were examined. Based on cytotoxicity and recombination induced by etoposide in different repair-deficient genetic backgrounds, double-strand DNA breaks generated by topoisomerase II appear to be repaired primarily by the single-strand invasion pathway of homologous recombination. Non-homologous end joining also was triggered by etoposide treatment, but this pathway was considerably less active than single-strand invasion and did not contribute significantly to cell survival in S.cerevisiae.
引用
收藏
页码:4373 / 4384
页数:12
相关论文
共 103 条
[1]  
Aguilera A, 2000, YEAST, V16, P731, DOI 10.1002/1097-0061(20000615)16:8<731::AID-YEA586>3.0.CO
[2]  
2-L
[3]  
ALANI E, 1989, GENETICS, V122, P47
[4]   THE PRODUCTION OF CHROMOSOMAL ALTERATIONS IN HUMAN-LYMPHOCYTES BY DRUGS KNOWN TO INTERFERE WITH THE ACTIVITY OF DNA TOPOISOMERASE-II .1. M-AMSA [J].
ANDERSSON, HC ;
KIHLMAN, BA .
CARCINOGENESIS, 1989, 10 (01) :123-130
[5]   Mutagenic properties of topoisomerase-targeted drugs [J].
Baguley, BC ;
Ferguson, LR .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :213-222
[6]  
BECK WT, 1993, ADV ENZYME REGUL, V33, P113
[7]   MECHANISMS OF MULTIDRUG RESISTANCE IN HUMAN TUMOR-CELLS - THE ROLES OF P-GLYCOPROTEIN, DNA TOPOISOMERASE-II, AND OTHER FACTORS [J].
BECK, WT .
CANCER TREATMENT REVIEWS, 1990, 17 :11-20
[8]   Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme [J].
Burden, DA ;
Osheroff, N .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :139-154
[9]   Removal of a single α-tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in Saccharomyces cerevisiae [J].
Burns, CG ;
Ohi, R ;
Mehta, S ;
O'Toole, ET ;
Winey, M ;
Clark, TA ;
Sugnet, CW ;
Ares, M ;
Gould, KL .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (03) :801-815
[10]   DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action [J].
Byl, JAW ;
Cline, SD ;
Utsugi, T ;
Kobunai, T ;
Yamada, Y ;
Osheroff, N .
BIOCHEMISTRY, 2001, 40 (03) :712-718